Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD+ and SIRT3
Ionica Masgras, Giuseppe Cannino, Francesco Ciscato, Carlos Sànchez‐Martìn, Fereshteh Babaei Darvishi, Francesca Scantamburlo, Marco Pizzi, Alessio Menga, Dolores Fregona, Alessandra Castegna, Andrea Rasola
Abstract
Abstract Neurofibromin loss drives neoplastic growth and a rewiring of mitochondrial metabolism. Here we report that neurofibromin ablation dampens expression and activity of NADH dehydrogenase, the respiratory chain complex I, in an ERK-dependent fashion, decreasing both respiration and intracellular NAD + . Expression of the alternative NADH dehydrogenase NDI1 raises NAD + /NADH ratio, enhances the activity of the NAD + -dependent deacetylase SIRT3 and interferes with tumorigenicity in neurofibromin-deficient cells. The antineoplastic effect of NDI1 is mimicked by administration of NAD + precursors or by rising expression of the NAD + deacetylase SIRT3 and is synergistic with ablation of the mitochondrial chaperone TRAP1, which augments succinate dehydrogenase activity further contributing to block pro-neoplastic metabolic changes. These findings shed light on bioenergetic adaptations of tumors lacking neurofibromin, linking complex I inhibition to mitochondrial NAD + /NADH unbalance and SIRT3 inhibition, as well as to down-regulation of succinate dehydrogenase. This metabolic rewiring could unveil attractive therapeutic targets for neoplasms related to neurofibromin loss.